CONFORMED COPY
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 30, 2005
-------------------------
CAMBREX CORPORATION
-------------------------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
DELAWARE 1-10638 22-2476135
-------------------------------------------------------------------------------
(State or other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
ONE MEADOWLANDS PLAZA, EAST RUTHERFORD, NEW JERSEY 07073
-------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (201) 804-3000
------------------------
Check the appropriate box if the Form 8K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (See General Instruction A.2 below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(d) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
CAMBREX CORPORATION
Form 8-K
Current Report
September 30, 2005
Section 5 - Corporate Governance and Management
Item 5.02. Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers.
(1) 5.02(b)
Cambrex Corporation is reporting under Item 5.02(b) that on
September 26, 2005, N. David Eansor, President, Cambrex Bioproducts,
resigned to pursue other interests. On September 30, 2005, Cambrex
Corporation issued a press release announcing Mr. Eansor's resignation.
(2) 5.02(c)
Cambrex Corporation is reporting under Item 5.02(c) that
effective September 30, 2005, Cambrex appointed Shawn P. Cavanaugh,
Senior Vice President and General Manager, Cambrex Bioproducts to replace
N. David Eansor. On September 30, 2005, Cambrex Corporation issued a
press release announcing the appointment of Mr. Cavanaugh.
Mr. Cavanagh joined Cambrex in October 1999 with the acquisition
of FMC BioProducts. Thereafter, Mr. Cavanaugh held various positions
with Cambrex subsidiaries. In 2000, he was promoted to the position of
Global Director, Endotoxin Detection and in 2004 to the position of Vice
President, Cambrex Bioproducts. Prior to joining Cambrex, Mr. Cavanagh
held various Management and Engineering positions with FMC BioProducts
and Eveready Battery Company from 1988 to 1999.
Item 9.01 - Financial Statements and Exhibits
(c) Exhibits
(99.1) Press release issued by Cambrex Corporation dated
September 30, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on behalf by the undersigned
hereunto duly authorized.
CAMBREX CORPORATION
Date: September 30, 2005 By: /s/ Peter E. Thauer
-------------------- --------------------------
Name: Peter E. Thauer
Title: Senior Vice President, General
Counsel and Corporate Secretary
Exhibit 99.1 Cambrex Corporation Press release dated September 30, 2005.